A New Ocular Therapeutics ToolLooking for business opportunities

Timo KangastupaCEO, Visionisti Oynon-confidential

““Dose reduction and convenience

technologies are needed”

Kevin BuehlerFormer Alcon Division Head

Novartis Investor Day22 November 2013

A new solution for suprachoroidal injections

Suitable also for precisely transmitting heat, cold, electricity, light or other energy to directly stimulate, damage, or heal a specific tissue or for diagnostic purposes

30-50M patients with AMDout of whom 3-10M have the wet form - an overwhelming burden

67M with glaucomauveitis, corneal infections, gene therapy, stem cell treatments, and others

350M with diabetic retinopathypotential therapies for oedemas, RVO, and others

10% continued growthprojected, driven by new indications

““An effective drug delivery system for the

back of the eye should embody four general characteristics. Current methods cannot meet all of these requirements.”

- SR Patel, Co-founder Clearside Biomedical

1.Minimally invasive and safe

to avoid the complications caused by the procedure

Fulfilled by Visionist’s Tool:

• No need for a surgical operation – in office procedure

• Closes the entry wound automatically

• Minimizes the risk for endophthalmitis

• Less discomfort for the patients and faster wound healing

2.Well targeted to the

desired tissueshigh bioavailability while reducing

adverse events and toxicity

Fulfilled by Visionist’s Tool:

• Direct contact to the sites of therapeutic action

• Effective distribution and faster influence

• Limits exposure to other regions of the eye

• Less side effects and complications

• Does not effect the optical axis

3.Capable of sustained delivery

to reduce the frequency of administration and allow for better therapeutic control

Fulfilled by Visionist’s Tool:

• Higher drug concentrations for months

• More accurate dosing and dose sparing

• Suitable for sustained delivery and implants

• Eases the treatment burden for all parties

4.Simple

to reduce errors and compliance problems

Fulfilled by Visionist’s Tool:

• Disposable product with great margins

• Stabilizes the eye and keeps the lids open

• Standardizes the procedure and increases the efficiency

• Repeatable, Faster, Easier and Safer

• Enables administration by trained non-physicians?

Proof of concept – ex vivo porcine eyes

• The distribution of methylene blue in the suprachoroidal space (black arrows).

• 1 μm FluoSpheres (below in red) were localized in the suprachoroidal space.

CONCLUSIONS: The proprietary ocular injection device is well suitable for precise delivery of injected material into suprachoroidal space.

Data on file

IPR

FreshPCT patent

pendingfor the Device and Methods

No countries chosen yet

FTO

Thoroughlyanalysed

No obstacles

Registered Community

Designs in EU

Business opportunities

Rare technology, rare opportunity.

Superior to the known alternatives for suprachoroidal drug delivery.

Visionisti Oy is open for any kind of business opportunities you are interested in.

Visionisti presents a novel delivery platform for your molecules, with no limitations.

Thank you!Please get in touch with any questions

You can reach me at timo@vsn.st